EGFR mutation status and brain metastases in non-small cell lung cancer: An understudied problem

Jonathan Riess, Seema Nagpal

Research output: Contribution to journalArticle

Abstract

Metastases to the central nervous system (CNS) in patients with non-small cell lung cancer (NSCLC) often herald a poor prognosis and a significant decrement in quality of life. Despite the substantial number of NSCLC patients who develop CNS metastases, there are few trials specifically addressing outcomes in these patients (1); many NSCLC trials studying systemic treatment exclude patients with active brain metastases. Dr. Welsh and colleagues recently published an article addressing this understudied population. They enrolled 40 NSCLC patients with brain metastases who went on to receive WBRT with concurrent administration of the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), erlotinib (2).

Original languageEnglish (US)
Pages (from-to)54-56
Number of pages3
JournalTranslational Cancer Research
Volume2
Issue number1
DOIs
StatePublished - Feb 1 2013
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this